Patient general characteristics and clinical features
Variable . | All (n = 49) . | DLI (n = 30) . | EBV-CTL (n = 19) . | P . |
---|---|---|---|---|
Median age at T-cell treatment, y (IQR) | 29 (16-47) | 33 (24-52) | 13 (8-44) | < .01 |
Sex | ||||
Female | 18 (36) | 14 (47) | 4 (21) | .13 |
Male | 31 (64) | 16 (53) | 15 (79) | |
HLA match | ||||
MMREL or MMUREL | 16 (33) | 3 (10) | 13 (68) | < .01 |
MREL | 21 (43) | 18 (60) | 3 (16) | |
MUR | 12 (24) | 9 (30) | 3 (16) | |
BMT type | ||||
T-cell depleted | 43 (88) | 29 (97) | 14 (74) | .03 |
Others | 6 (12) | 1 (3) | 5 (26) | |
Immunosuppressive medication* | 14 (28.6) | 6 (20) | 8 (42) | .32 |
Presenting symptoms and/or PE findings | ||||
Fever | 30 (61) | 18 (60) | 12 (63) | |
Lymphoadenopathy | 21 (43) | 15 (50) | 6 (31) | |
Enlarged tonsils/sore throat | 15 (31) | 11 (37) | 4 (21) | |
EBV PCR positivity | 12 (24) | 6 (20) | 6 (31) | |
Abdominal pain | 8 (16) | 5 (16) | 3 (16) | |
Nausea/vomiting | 6 (12) | 4 (13) | 2 (11) | |
Neurologic symptoms† | 4 (9) | 2 (6) | 2 (11) | |
Hepatomegaly and/or splenomegaly | 4 (9) | 1 (3) | 3 (16) | |
Jaundice | 3 (6) | 3 (10) | 0 (0) | |
Diarrhea | 3 (6) | 1 (3) | 2 (11) | |
None | 2 (4) | 1 (3) | 1 (5) | |
Sites involved in disease (clinical and/or radiologic) | ||||
Lymph nodes | 38 (78) | 23 (77) | 15 (79) | |
Waldeyer ring | 21 (43) | 16 (53) | 5 (26) | |
Liver | 16 (33) | 9 (30) | 7 (37) | |
Lung | 18 (36) | 14 (47) | 4 (21) | |
Gastrointestinal tract | 14 (29) | 8 (26) | 6 (31) | |
Spleen | 7 (14) | 4 (13) | 3 (16) | |
CNS/spine | 6 (12) | 4 (13) | 2 (11) | |
Pancreas | 1 (2) | 1 (3) | 0 (0) | |
Thyroid | 1 (2) | 1 (3) | 0 (0) | |
Larynx | 1 (2) | 1 (3) | 0 (0) | |
Median time to EBV-LPD after HSCT, d (IQR) | 102.5 (64-247) | 113 (84-138) | 91 (64-247) |
Variable . | All (n = 49) . | DLI (n = 30) . | EBV-CTL (n = 19) . | P . |
---|---|---|---|---|
Median age at T-cell treatment, y (IQR) | 29 (16-47) | 33 (24-52) | 13 (8-44) | < .01 |
Sex | ||||
Female | 18 (36) | 14 (47) | 4 (21) | .13 |
Male | 31 (64) | 16 (53) | 15 (79) | |
HLA match | ||||
MMREL or MMUREL | 16 (33) | 3 (10) | 13 (68) | < .01 |
MREL | 21 (43) | 18 (60) | 3 (16) | |
MUR | 12 (24) | 9 (30) | 3 (16) | |
BMT type | ||||
T-cell depleted | 43 (88) | 29 (97) | 14 (74) | .03 |
Others | 6 (12) | 1 (3) | 5 (26) | |
Immunosuppressive medication* | 14 (28.6) | 6 (20) | 8 (42) | .32 |
Presenting symptoms and/or PE findings | ||||
Fever | 30 (61) | 18 (60) | 12 (63) | |
Lymphoadenopathy | 21 (43) | 15 (50) | 6 (31) | |
Enlarged tonsils/sore throat | 15 (31) | 11 (37) | 4 (21) | |
EBV PCR positivity | 12 (24) | 6 (20) | 6 (31) | |
Abdominal pain | 8 (16) | 5 (16) | 3 (16) | |
Nausea/vomiting | 6 (12) | 4 (13) | 2 (11) | |
Neurologic symptoms† | 4 (9) | 2 (6) | 2 (11) | |
Hepatomegaly and/or splenomegaly | 4 (9) | 1 (3) | 3 (16) | |
Jaundice | 3 (6) | 3 (10) | 0 (0) | |
Diarrhea | 3 (6) | 1 (3) | 2 (11) | |
None | 2 (4) | 1 (3) | 1 (5) | |
Sites involved in disease (clinical and/or radiologic) | ||||
Lymph nodes | 38 (78) | 23 (77) | 15 (79) | |
Waldeyer ring | 21 (43) | 16 (53) | 5 (26) | |
Liver | 16 (33) | 9 (30) | 7 (37) | |
Lung | 18 (36) | 14 (47) | 4 (21) | |
Gastrointestinal tract | 14 (29) | 8 (26) | 6 (31) | |
Spleen | 7 (14) | 4 (13) | 3 (16) | |
CNS/spine | 6 (12) | 4 (13) | 2 (11) | |
Pancreas | 1 (2) | 1 (3) | 0 (0) | |
Thyroid | 1 (2) | 1 (3) | 0 (0) | |
Larynx | 1 (2) | 1 (3) | 0 (0) | |
Median time to EBV-LPD after HSCT, d (IQR) | 102.5 (64-247) | 113 (84-138) | 91 (64-247) |